vs

Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Victoria's Secret & Co. (VSCO). Click either name above to swap in a different company.

Victoria's Secret & Co. is the larger business by last-quarter revenue ($1.5B vs $766.2M, roughly 1.9× BIOMARIN PHARMACEUTICAL INC). BIOMARIN PHARMACEUTICAL INC runs the higher net margin — 13.8% vs -2.5%, a 16.3% gap on every dollar of revenue. On growth, Victoria's Secret & Co. posted the faster year-over-year revenue change (9.3% vs 3.0%). Over the past eight quarters, BIOMARIN PHARMACEUTICAL INC's revenue compounded faster (3.7% CAGR vs -15.9%).

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Victoria's Secret is an American lingerie, clothing and beauty retailer. Founded in 1977 by Stanford graduate student Roy Raymond and his wife Gaye, the company's five lingerie stores were sold to Les Wexner in 1982. Wexner rapidly expanded into American shopping malls, expanding the company into 350 stores nationally with sales of $1 billion by the early 1990s, when Victoria's Secret became the largest lingerie retailer in the United States.

BMRN vs VSCO — Head-to-Head

Bigger by revenue
VSCO
VSCO
1.9× larger
VSCO
$1.5B
$766.2M
BMRN
Growing faster (revenue YoY)
VSCO
VSCO
+6.3% gap
VSCO
9.3%
3.0%
BMRN
Higher net margin
BMRN
BMRN
16.3% more per $
BMRN
13.8%
-2.5%
VSCO
Faster 2-yr revenue CAGR
BMRN
BMRN
Annualised
BMRN
3.7%
-15.9%
VSCO

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
BMRN
BMRN
VSCO
VSCO
Revenue
$766.2M
$1.5B
Net Profit
$106.0M
$-37.0M
Gross Margin
74.6%
36.4%
Operating Margin
16.9%
-1.3%
Net Margin
13.8%
-2.5%
Revenue YoY
3.0%
9.3%
Net Profit YoY
33.9%
EPS (diluted)
$0.54
$-0.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMRN
BMRN
VSCO
VSCO
Q1 26
$766.2M
Q4 25
$874.6M
$1.5B
Q3 25
$776.1M
$1.5B
Q2 25
$825.4M
$1.4B
Q1 25
$745.1M
$2.1B
Q4 24
$747.3M
$1.3B
Q3 24
$745.7M
$1.4B
Q2 24
$712.0M
$1.4B
Net Profit
BMRN
BMRN
VSCO
VSCO
Q1 26
$106.0M
Q4 25
$-46.6M
$-37.0M
Q3 25
$-30.7M
$16.0M
Q2 25
$240.5M
$-2.0M
Q1 25
$185.7M
$193.0M
Q4 24
$124.9M
$-56.0M
Q3 24
$106.1M
$32.0M
Q2 24
$107.2M
$-4.0M
Gross Margin
BMRN
BMRN
VSCO
VSCO
Q1 26
74.6%
Q4 25
68.5%
36.4%
Q3 25
82.0%
35.6%
Q2 25
81.8%
35.0%
Q1 25
79.7%
38.6%
Q4 24
81.8%
34.7%
Q3 24
74.7%
35.4%
Q2 24
81.7%
36.9%
Operating Margin
BMRN
BMRN
VSCO
VSCO
Q1 26
16.9%
Q4 25
-5.1%
-1.3%
Q3 25
-6.0%
2.8%
Q2 25
33.5%
1.5%
Q1 25
30.0%
12.8%
Q4 24
21.6%
-3.5%
Q3 24
15.3%
4.4%
Q2 24
16.9%
1.9%
Net Margin
BMRN
BMRN
VSCO
VSCO
Q1 26
13.8%
Q4 25
-5.3%
-2.5%
Q3 25
-4.0%
1.1%
Q2 25
29.1%
-0.1%
Q1 25
24.9%
9.2%
Q4 24
16.7%
-4.2%
Q3 24
14.2%
2.3%
Q2 24
15.1%
-0.3%
EPS (diluted)
BMRN
BMRN
VSCO
VSCO
Q1 26
$0.54
Q4 25
$-0.22
$-0.46
Q3 25
$-0.16
$0.20
Q2 25
$1.23
$-0.02
Q1 25
$0.95
$2.41
Q4 24
$0.65
$-0.71
Q3 24
$0.55
$0.40
Q2 24
$0.55
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMRN
BMRN
VSCO
VSCO
Cash + ST InvestmentsLiquidity on hand
$2.2B
$249.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.2B
$653.0M
Total Assets
$8.6B
$5.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMRN
BMRN
VSCO
VSCO
Q1 26
$2.2B
Q4 25
$1.3B
$249.0M
Q3 25
$1.3B
$188.0M
Q2 25
$1.2B
$138.0M
Q1 25
$1.0B
$227.0M
Q4 24
$942.8M
$161.0M
Q3 24
$675.4M
$169.0M
Q2 24
$972.1M
$105.0M
Stockholders' Equity
BMRN
BMRN
VSCO
VSCO
Q1 26
$6.2B
Q4 25
$6.1B
$653.0M
Q3 25
$6.1B
$680.0M
Q2 25
$6.0B
$645.0M
Q1 25
$5.8B
$640.0M
Q4 24
$5.7B
$429.0M
Q3 24
$5.4B
$472.0M
Q2 24
$5.3B
$423.0M
Total Assets
BMRN
BMRN
VSCO
VSCO
Q1 26
$8.6B
Q4 25
$7.6B
$5.1B
Q3 25
$7.6B
$4.8B
Q2 25
$7.5B
$4.6B
Q1 25
$7.1B
$4.5B
Q4 24
$7.0B
$4.9B
Q3 24
$6.9B
$4.6B
Q2 24
$7.1B
$4.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMRN
BMRN
VSCO
VSCO
Operating Cash FlowLast quarter
$220.7M
$-180.0M
Free Cash FlowOCF − Capex
$-232.0M
FCF MarginFCF / Revenue
-15.8%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
2.08×
TTM Free Cash FlowTrailing 4 quarters
$309.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMRN
BMRN
VSCO
VSCO
Q1 26
$220.7M
Q4 25
$99.6M
$-180.0M
Q3 25
$368.7M
$156.0M
Q2 25
$185.3M
$-150.0M
Q1 25
$174.4M
$674.0M
Q4 24
$185.6M
$-248.0M
Q3 24
$221.5M
$115.0M
Q2 24
$118.8M
$-116.0M
Free Cash Flow
BMRN
BMRN
VSCO
VSCO
Q1 26
Q4 25
$58.9M
$-232.0M
Q3 25
$340.2M
$88.0M
Q2 25
$168.2M
$-193.0M
Q1 25
$157.6M
$646.0M
Q4 24
$166.1M
$-299.0M
Q3 24
$203.0M
$55.0M
Q2 24
$97.4M
$-155.0M
FCF Margin
BMRN
BMRN
VSCO
VSCO
Q1 26
Q4 25
6.7%
-15.8%
Q3 25
43.8%
6.0%
Q2 25
20.4%
-14.3%
Q1 25
21.2%
30.7%
Q4 24
22.2%
-22.2%
Q3 24
27.2%
3.9%
Q2 24
13.7%
-11.4%
Capex Intensity
BMRN
BMRN
VSCO
VSCO
Q1 26
Q4 25
4.7%
3.5%
Q3 25
3.7%
4.7%
Q2 25
2.1%
3.2%
Q1 25
2.3%
1.3%
Q4 24
2.6%
3.8%
Q3 24
2.5%
4.2%
Q2 24
3.0%
2.9%
Cash Conversion
BMRN
BMRN
VSCO
VSCO
Q1 26
2.08×
Q4 25
Q3 25
9.75×
Q2 25
0.77×
Q1 25
0.94×
3.49×
Q4 24
1.49×
Q3 24
2.09×
3.59×
Q2 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BMRN
BMRN

Segment breakdown not available.

VSCO
VSCO

Sales Channel North America Stores$778.0M53%
Sales Channel Directly To Consumer$429.0M29%
Sales Channel International$265.0M18%
Sales Channel Loyalty And Private Label Credit Card$19.0M1%

Related Comparisons